Dr. William Leaf-Herrmann, partner, leads the firm’s North American life science practice. He has more than 25 years of experience in structuring and developing corporate, therapeutic, product, and portfolio strategies for clients in the pharmaceutical and biotechnology industries.
Dr. Leaf-Herrmann, who began his consulting career at SDG in 1993, returned to the firm in 2021 after several years as a senior principal with IQVIA, a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA was formed from the merger of Quintiles and IMS Health. Dr. Leaf-Herrmann had previously been a senior principal with IMS Health and a vice president for Analysis Group, an economics consulting firm.
Dr. Leaf-Herrmann’s clients have included many top companies in the industry, including seven of the top 10 global pharmaceutical companies, three of the largest Japanese pharmaceutical companies, and medical device, diagnostic, and generics companies.
Dr. Leaf-Herrmann’s experience spans a broad spectrum of interdisciplinary projects, including supporting clients in corporate valuation, commercial strategy, portfolio strategy, therapeutic area strategy, and commercial strategy. He has designed and implemented portfolio management processes for global pharmaceutical companies’ R&D portfolios. He is experienced in the application of decision science and in the structuring and evaluation of complex strategic alternatives.
Dr. Leaf-Herrmann holds a PhD in physics from Harvard University and a bachelor of science in physics and applied mathematics from Purdue University. He is based in Brookline, Mass., outside of Boston.